Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379892 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2DRD2 | |
| SCHEMBL21069554 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2TNF | |
| SCHEMBL21106493 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2TNF | |
| SCHEMBL24764991 | 0.89 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2 | |
| SCHEMBL21107342 | 0.89 | CRBN (0.61) | CRBNDDB1IKZF3IKZF2DRD2 | |
| SCHEMBL21069482 | 0.89 | CRBN (0.61) | CRBNDDB1IKZF3IKZF2DRD2 | |
| SCHEMBL24764988 | 0.88 | CRBN (0.57) | CRBNDDB1IKZF3IKZF2DRD2 | |
| SCHEMBL24764683 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF3IKZF2TNF | |
| SCHEMBL24765085 | 0.87 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2 | |
| SCHEMBL24765896 | 0.87 | CRBN (0.60) | CRBNDDB1IKZF3IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.